It also encourages collaboration among enterprises, hospitals, and research institutions to foster impactful AI applications throughout the pharmaceutical sector.

Fangzhou continues to innovate within its 'H2H Smart Healthcare Ecosystem', showcasing practical applications of AI that enhance healthcare accessibility and patient care.

The company is dedicated to improving healthcare experiences by leveraging AI and big data technologies within its ecosystem.

Dr. Xie Fangmin, CEO of Fangzhou, has reiterated the company's commitment to supporting China's healthcare blueprint through technological innovations that align with national priorities.

He emphasized that Fangzhou's initiatives are in line with China's 'AI + Healthcare' strategy, ensuring compliance with regulatory standards.

Dr. Xie Fangmin's leadership reflects a strong dedication to advancing China's AI and healthcare initiatives through innovative solutions.

Fangzhou Inc. is emerging as a leader in the healthcare sector with its innovative 'AI + H2H Smart Healthcare Ecosystem', which aims to enhance chronic disease management and improve healthcare accessibility.

This Implementation Plan highlights the critical role of digital transformation through AI, big data, and advanced technologies to boost pharmaceutical development and production.

As of the end of 2024, Fangzhou has built a robust infrastructure for AI integration in healthcare, boasting 49.2 million registered users and 223,000 physicians.

The company's continuous technological advancements significantly enhance chronic disease management through effective AI integration.

China's pharmaceutical industry is currently undergoing a digital transformation, as detailed in the 2025-2030 Pharmaceutical Industry Digital Transformation Implementation Plan issued by key regulatory bodies.